AML-029 Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3–Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)

Journal article

Peer reviewed

Harry Erba, Pau Montesinos, Radovan Vrhovac, Elzbieta Patkowska, Hee-Je Kim, Pavel Zak, Po-Nan Wang, Tsvetomir Mitov, James Hanyok, Li Liu, …

Clinical lymphoma, myeloma and leukemia, Vol.22, pp.S208-S209

2022-10

Metrics

1 Record Views

Title: AML-029 Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3–Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)
Creators: Harry Erba
Pau Montesinos
Radovan Vrhovac
Elzbieta Patkowska
Hee-Je Kim
Pavel Zak
Po-Nan Wang
Tsvetomir Mitov
James Hanyok
Li Liu
Aziz Benzohra
Arnaud Lesegretain
Jorge Cortes
Alexander Perl
Mikkael Sekeres
Hervé Dombret
Sergio Amadori
Jianxiang Wang
Mark Levis
Richard Schlenk
Publication Details: Clinical lymphoma, myeloma and leukemia, Vol.22, pp.S208-S209
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031759763102976